Printer Friendly

SEARLE AND WYETH-AYERST CO-PROMOTE ONLY ONCE-A-DAY QUINOLONE ANTIBIOTIC

SEARLE AND WYETH-AYERST CO-PROMOTE ONLY ONCE-A-DAY QUINOLONE ANTIBIOTIC
 NEW YORK, July 21 /PRNewswire/ -- Searle and Wyeth-Ayerst announced today the availability of Maxaquin(R) (lomefloxacin HCl), the only once- a-day quinolone antibiotic, which they are co-promoting in the United States.
 Maxaquin, approved for marketing earlier this year, is -- among other indications -- the only one tablet, once-a-day, broad-spectrum quinolone indicated for mild-to-moderate complicated and uncomplicated urinary tract infections (UTIs). UTIs are the most common bacterial infections in the United States, accounting for 8 to 10 million physician office visits annually. In addition to common bacteria, Maxaquin is effective against bacteria that are developing resistance to standard UTI therapy.
 To highlight the effectiveness of the agent's one tablet, once-a-day dosing, Searle and Wyeth-Ayerst introduced the MaxaCURE program for UTI patients. In the program, if a patient develops another UTI within six months of completing a full course of Maxaquin therapy, the next prescription for the antibiotic is free. "In creating the MaxaCURE program, we want to demonstrate our complete confidence in our once-a- day dosing," said V.N. (Andy) Anderson, president of Searle U.S. operations.
 Searle and Wyeth-Ayerst officials also released data showing both patients and physicians would prefer one-a-day antibiotics, if they knew them to be as effective as drugs requiring multiple doses. Most patients (77 percent) believe a once-a-day antibiotic would make it easier to complete a full course of therapy. Nearly all physicians (90 percent) said a once-a-day antibiotic would be valuable in helping patients adhere to their prescriptions, and nearly as many physicians (87 percent) said that a one-strength, one tablet daily regimen would simplify their prescribing process. The surveys, conducted by the Gallup Organization, interviewed 75 physicians and 300 patients who had recently been on antibiotics.
 In the treatment of UTIs, Maxaquin is indicated for mild-to-moderate complicated infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Citrobacter diversus, and Enterobacter cloacae and for mild-to-moderate uncomplicated infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Staphylococcus saprophyticus. The efficacy and safety of lomefloxacin in treating patients with Pseudomonas bacteremia has not been established.
 Beyond the treatment of UTIs, Maxaquin is also indicated for acute bacterial exacerbations of chronic bronchitis caused by Haemophilus influenzae and Moraxella catarrhalis, the two most prevalent bacteria associated with this lower respiratory infection; Maxaquin is not indicated when the condition is caused by Streptococcus pneumoniae. Additionally, Maxaquin is the first antimicrobial agent indicated to reduce infectious complications that can follow the post-operative period (3 to 5 days) of transurethral surgery, though it is not indicated for minor urologic procedures.
 Unlike other quinolones, Maxaquin does not interact with theophylline in a clinically significant way. Theophylline is widely used for such breathing disorders as chronic bronchitis, asthma and emphysema, and accounts for approximately 26 million prescriptions in the United States annually.
 Searle is a research-based pharmaceutical company that develops, manufactures and markets prescription pharmaceuticals worldwide. It is a wholly-owned subsidiary of Monsanto (NYSE: MTC).
 Wyeth-Ayerst is a division of American Home Products Corporation (NYSE: AHP), a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostic equipment, over-the-counter medicines and food products. The Wyeth-Ayerst division is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and infant nutritionals.
 Maxaquin is a registered trademark of G.D. Searle & Co.
 -0- 7/21/92
 /CONTACT: Kim Piekos of G.D. Searle, 708-470-6716; Audrey Ashby of Wyeth-Ayerst, 215-971-5823; or Kevin Donovan, 212-397-4140, for G.D. Searle/
 (MTC AHP) CO: G.D. Searle & Co.; Wyeth-Ayerst ST: New York, Pennsylvania IN: MTC SU:


LR-TQ -- NY002 -- 1082 07/21/92 08:06 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 21, 1992
Words:613
Previous Article:SAAB AUTOMOBILE AB NAMES HRUSCHKA ASSOCIATE REGIONAL DIRECTOR, JAPAN; SWEDISH AUTOMAKER RELOCATES OFFICE IN JAPAN
Next Article:CALLAWAY GOLF REPORTS RECORD SALES AND EARNINGS FOR THE JUNE QUARTER
Topics:


Related Articles
SYNTEX RECEIVES APPROVAL FOR ADDITIONAL TORADOL IM SYRINGE SUPPLIER
WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY ANNOUNCE FLU VACCINE AGREEMENT
BURROUGHS WELLCOME CO. AND WYETH-AYERST TO CO-PROMOTE NEW TREATMENT FOR CHICKENPOX
SEARLE AND WYETH-AYERST TO CO-PROMOTE MAXAQUIN
WYETH-AYERST AND PANLABS SIGN RESEARCH COLLABORATION
WYETH-AYERST AND OPHIDIAN PHARMACEUTICALS TO DEVELOP IMPROVED ANTIDOTES FOR POISONOUS SNAKEBITE
ChemGenics and American Home Products Announce Collaboration in Antibacterial Drug Discovery
Wyeth-Ayerst International to Market New Alzheimer's Disease Treatment
Elan and Wyeth-Ayerst to Expand Naprelan(R) Promotion; Athena to Co-Promote Naprelan Through New Sales Force
Scios and Wyeth-Ayerst Terminate Co-Promotion Agreement for Antidepressant Drug, Effexor(R)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters